论文部分内容阅读
目的 :研究嗜血流感杆菌耐药性。方法 :对 1994年 7月至 1996年 8月收治的下呼吸道感染患者嗜血流感杆菌感染 5 6例 ,测其 β-内酰胺酶 ,及对 11种抗菌药物进行耐药监测。结果 :β-内酰胺酶阳性株占 4 5 %,荚膜血清型非 b型占 96%,结果表明其中 15株产酶菌对青霉素 (PCG)、氨苄西林(ABPC)、哌拉西林 (PIPC)较非产酶株呈现耐药 ,5 6例患者病原菌确定为嗜血流感杆菌后采用敏感药头孢克洛治疗 ,临床有效率达 89%,细菌阴转率为 94 %。结论 :产酶株耐药发生率高 ,头孢克洛是一安全、有效治疗嗜血流感杆菌的药物。
Objective: To study the drug resistance of Haemophilus influenzae. Methods: From July 1994 to August 1996, 56 patients with H.pylori infection in lower respiratory tract infection were enrolled. The β-lactamases were tested and the drug resistance of 11 antimicrobial agents was monitored. Results: β-lactamase positive strains accounted for 45%, non-b capsule serotypes accounted for 96%, the results showed that 15 strains of bacteria producing penicillin (PCG), ampicillin (ABPC), piperacillin (PIPC ) Were more resistant than non-enzyme-producing strains. The pathogens in 56 patients were determined to be bacillus dengue bacillus by cefaclor. The clinical effective rate was 89% and the bacterial negative conversion rate was 94%. Conclusion: The incidence of drug-resistant strains is high, cefaclor is a safe and effective drug for the treatment of Haemophilus influenzae.